Prostate apoptosis response protein 4 (Par-4) also known as PRKC apoptosis WT1 regulator is a tumor suppressor that selectively induces apoptosis in cancer cells. However, its post-translational regulation by ubiquitin-mediated proteolysis and the cellular machinery that is responsible for its proteasomal degradation are unknown. Using immunopurification and an unbiased mass spectrometry-based approach, we show that Par-4 interacts with the SPRY-domain containing E3 ubiquitin ligase Fbxo45 through a short consensus sequence motif. Fbxo45 interacts with Par-4 in the cytoplasm and mediates its ubiquitylation and proteasomal degradation. Fbxo45 silencing results in stabilization of Par-4 with increased apoptosis. Importantly, a Par-4 mutant that is unable to bind Fbxo45 is stabilized and further enhances staurosporine-induced apoptosis. Co-expression of Fbxo45 with Par-4 protects cancer cells against Par-4-induced apoptosis. Our studies reveal that Fbxo45 is the substratereceptor subunit of a functional E3 ligase for Par-4 that has a critical role in cancer cell survival.
F-box proteins are the substrate-specific adaptor subunits of SCF (Skp1, CUL1, F-box protein) E3 ubiquitin ligase complexes that promote proteasomal degradation of critical cellular regulators. [1] [2] [3] [4] [5] [6] Previous studies have shown that in contrast to other F-box proteins that assemble SCF ubiquitin ligase complexes, Fbxo45 forms an atypical ubiquitin ligase complex that contains Skp1 and the Ring-finger protein PAM (protein-associated with myc) also known as MYCBP2 (mycbinding protein 2). 7, 8 Fbxo45 has been linked to the proteasomal degradation of a few targets including p73 9 and Munc13-1. 10 Fbxo45 is one of only six F-box proteins that are conserved in metazoans and the only F-box protein known to contain a SPRY domain, 3 which was first identified as a sequence repeat in the dual-specificity kinase splA and ryanodine receptors. 11 SPRY domains are present in more than 150 human proteins that cover a wide spectrum of biological functions, including regulation of cytokine signaling and innate retroviral restriction. 12 The crystal structure of the SPRY domain has been determined in complex with a 20 amino-acid residue peptide derived from the VASA protein. These observations led to the identification of a short sequence motif in Par-4 (ELNNNL) recognized by the SPRY domain. 13 Par-4 was first identified in prostate cancer cells 14 where it selectively induces apoptosis in androgen-independent and Ras-transformed cells but not in androgen-dependent cancer cells or normal prostate epithelial cells. 15 The human Par-4 gene maps to chromosome 12q21, a region frequently deleted in malignancies, and encodes a protein (38 kDa) containing conserved functional domains, which include two putative nuclear localization sequences (NLSs), designated NLS1 and NLS2; a leucine zipper domain spanning amino acids 290-332 in the C-terminal region and a nuclear export sequence in the C-terminus. 16 Par-4 localizes both to the cytoplasm and the nucleus in many cancer cells. 15, 16 Par-4 induces apoptosis in hormoneindependent cancer cells by enabling the translocation of Fas and Fas ligand (Fas/FasL) to the plasma membrane. 17 In parallel, Par-4 translocates to the nucleus and inhibits NF-kBmediated cell survival mechanisms. 18 In other studies, Par-4 has been shown to function in the cytoplasm, where it represses NF-kB-dependent gene transcription by inhibiting the TNFa-induced nuclear translocation of the p65 (Rel A) subunit by blocking the atypical protein kinase C. 19 The apoptotic function of Par-4 requires its phosphorylation at the T155 residue by PKA and nuclear translocation. 20 On the other hand, phosphorylation of Par-4 by AKT inhibits apoptosis by interfering with the nuclear translocation of Par-4. 21 Par-4 is a bona fide tumor suppressor, which exhibits a potent pro-apoptotic function in cancer cells. 14, 19 Accordingly, Par-4 is mutated or silenced in a variety of human cancers. 22, 23 Consistent with its pro-apoptotic effects, transgenic mice ubiquitously expressing the SAC domain of are resistant to the growth of spontaneous and inducible tumors. 24, 25 Emerging data have implicated Par-4-induced multinucleation as a mechanism of cell death in oncogeneaddicted cells and establish Par-4 as a negative regulator of breast cancer recurrence. 26 In this study, we investigated whether endogenous Par-4 in cancer cells is regulated by proteasomal degradation and identified the cellular mechanism that regulates its ubiquitinmediated proteolysis thereby controlling its apoptotic function.
Results
Fbxo45 specifically interacts with Par-4. F-box proteins are the substrate-specific adaptor subunits of SCF E3 ubiquitin ligase complexes. [1] [2] [3] [4] [5] [6] To identify the candidate substrates of the Fbxo45 ubiquitin ligase, we isolated Fbxo45 immunocomplexes by transient expression of HA-tagged Fbxo45 in human U87MG cell, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The LC-MS/MS data revealed known members of the atypical SCF complex, Fbxo45, Skp1 and MYCBP2. The LC-MS/MS analysis also identified peptides corresponding to Par-4 (PAWR; Figure 1a ). These peptides were not found in the negative control (HA-tag only) immunopurification suggesting Par-4 as an interactor of Fbxo45.
We further examined the binding of Fbxo45 and Par-4 by immunoprecipitation and western blot analysis. We cotransfected V5-tagged Par-4 and HA-tagged Fbxo45 into 293T cells and demonstrated reciprocal co-immunoprecipitation of both proteins (Figure 1b) . To examine whether Par-4 interacts with endogenous Fbxo45, we expressed Flagtagged Par-4 in 293T cells and performed immunoprecipitation and western blot analysis. The results indicate that Par-4 interacts with endogenous Fbxo45 (Figure 1c) .
To assess the ability of Fbxo45 to reciprocally interact with endogenous Par-4 and investigate the specificity of the interaction, we screened eight human F-box proteins and found that only Fbxo45 was able to co-immunoprecipitate endogenous Par-4. (Figure 1d, Supplementary Figures 1a and b) .
Consistent with previous findings showing that Fbxo45 forms a complex with Skp1 and PAM (and its orthologs) in Drosophila, 27 Caenorhabditis elegans 7 and Mus musculus. 8 We confirmed that human Fbxo45 interacts with endogenous PAM and Skp1, but not with Cullin1 or Rbx1, by immunoprecipitation and western blotting (Supplementary Figure 1d) . Yeast two-hybrid analyses revealed that Fbxo45 bound to Skp1 through the F-box domain, and PAM via the SPRY domain (Supplementary Figure 1e) . Overall, these experiments confirm that human Fbxo45 forms an atypical multicomponent E3 ligase with Skp1 and PAM in a complex similar to what has been reported in other species. Given that Par-4 localizes both to the cytoplasm and the nucleus in many cancer cells and Par-4-mediated apoptosis requires the nuclear function of Par-4 protein, 15 we sought to determine the intracellular localization of its interaction with Fbxo45. To this end, the interaction between Par-4 and Fbxo45 was studied by immunoprecipitation and western blot analysis using lysates from cytoplasmic and nuclear fractions. The interaction was only found in the cytoplasm (Figure 2b) . Phosphorylation of Par-4 by AKT has been shown to interfere with its nuclear translocation by promoting Par-4 binding to protein 14-3-3 and restricting its localization to the cytoplasm. 21 Accordingly, we treated PC-3 cells with AKT kinase inhibitor (CAL-101) to promote Par-4 translocation to the nucleus. As shown in Figure 2c , CAL-101 treatment promoted Par-4 nuclear translocation and diminished the interaction between Par-4 and Fbxo45 in the cytoplasm.
Fbxo45 regulates the stability of Par-4 in the cytoplasm through proteasomal degradation. Having observed the interaction with the E3 ligase Fbxo45, we sought to determine whether Par-4 was regulated by proteasomal degradation. To examine this possibility, HeLa cells were treated with the proteasomal inhibitor MG132. After 1 h treatment, cells were exposed to cycloheximide for different times. Whole-cell extracts (WCEs) were analyzed to investigate the half-life of Par-4. Our results indicated that Par-4 has a half-life of B2 h in HeLa cells; after the treatment with MG132, Par-4 was stabilized and did not undergo significant degradation even at 6 h ( Figure 3a) . These results suggest that Par-4 levels are regulated by proteasome-mediated degradation.
Having observed a specific interaction between Fbxo45 and Par-4 ( Figure 1 ), we investigated whether Fbxo45 regulated the stability of Par-4. HeLa cells were transiently transfected with Scrambled or siRNA smart pool targeting Fbxo45. After 48 h of transfection, Fbxo45-depleted cells and control cells were treated with cycloheximide for different times. WCEs were analyzed to investigate the half-life of Par-4. As seen in Figure 3b , Par-4 has a half-life of B3 h in the control cells; but in the Fbxo45 knockdown cells, Par-4 was stabilized and its half-life was significantly increased (46 h; Po0.05). To confirm this observation, we stably silenced Fbxo45 in mouse embryonic stem (mES) cells using Fbxo45 shRNA and evaluated the half-life of Par-4. As shown in Figure 3c , mES cells expressing Fbxo45 shRNA showed Par-4 stabilization, whereas those expressing control shRNA showed faster Par-4 turnover with 480% decrease in Par-4 levels at 4-6 h of cycloheximide treatment.
In corollary experiments, we demonstrated that ectopic Fbxo45 expression promoted the degradation of Par-4 in Hela cells (Supplementary Figure 2a) . Interestingly, silencing or ectopic expression of another SPRY-contained protein TRIM 21 did not regulate the stabilization of Par-4 (Supplementary Figure 2b) . In addition, endogenous Par-4 was not stabilized by the neddylation inhibitor (MLN4924) treatment (Supplementary Figure 4) , thus suggesting that Par-4 proteasomal degradation is not mediated by a Cullin-ring ligase.
To determine whether the regulation between Fbxo45 and Par-4 also occurred in the cytoplasm, we assessed the level of Par-4 after treatment with the AKT inhibitor CAL-101. As seen 
that ectopic expression of wild-type Par-4 yielded higher apoptosis rates (20.9%) in comparison to control cells (6.6%), whereas co-expression of Fbxo45 (WT) and Par-4 reverted the apoptosis rate to near control levels (13.2%; Po0.05; Figure 5c ). However, reversion of the apoptosis rate was not observed when Fbxo45 (DSPRY) was co-expressed with Par-4 (Supplementary Figure 7) . Figure 8b) .
Discussion
Post-translational modifications including ubiquitylation and phosphorylation regulate the function of key signaling molecules by modulating their activity, localization and protein stability. 29 Par-4 is a tumor suppressor and a critical regulator of tumor cell survival. 14, 26 Subtle changes in regulation and alteration of Par-4 expression and localization may impact its biological function as a pro-apoptotic protein. In the present study, we provide evidence that the E3 ubiquitin ligase Fbxo45 interacts with Par-4 via its VASA-like sequence -a continuous six amino-acid peptide located in the N-terminal of Par-4 ( 68 ELNNNL 72 ), and that the interaction permits the polyubiquitylation and degradation of Par-4 in cancer cells. Mutation of the Par-4 degron affects its interaction with and degradation by Fbxo45. Importantly, we demonstrate that the Par-4 degron mutant that is unable to bind Fbxo45 is stabilized and further enhances staurosporine-induced apoptosis of cancer cells.
Fbxo45 is the only F-box protein known to contain a SPRY domain. 3 Besides Fbxo45, four mammalian suppressor of cytokine signaling (SOCS) box proteins (SSB-1 to -4) contain SPRY domains. The SOCS box-containing proteins, SSB-1 to SSB-4, belong to the SOCS box family of E3 ubiquitin ligases, which are likely to target proteins for ubiquitin-mediated degradation. Of these, SSB-1, SSB-2 and SSB-4, but not SSB-3 bind, with Par-4, 30 and the interaction between SOCS box family proteins and Par-4 requires the ELNNN motif (VASA-like sequence) of Par-4.
13,31 However, SSB-mediated regulation of Par-4 levels by proteasomal degradation has not been observed. 30 In this study, we have demonstrated that Fbxo45 through its SPRY domain interacts with the VASA-like sequence of Par-4 and mediates it ubiquitylation and degradation by the proteasome.
The pro-apoptotic function of Par-4 requires phosphorylation of Par-4 at the T155 residue and its nuclear translocation. 20 Cancer cells that exhibit impaired nuclear translocation of Par-4 are resistant to apoptosis. 15 Nuclear translocation of Par-4 is essential for inhibition of NF-kB-dependent transcriptional activity; binding to Par-4 partner proteins WT1, ZIPK/ DAXX and THAP; and induction of apoptosis. 15 AKT binding and phosphorylation of Par-4 result in its cytoplasmic retention and abrogation of apoptosis. 21 Our studies show that Fbxo45 interacts with Par-4 in the cytoplasm (Figures 2b  and c) , and mediates the proteasomal degradation of Par-4, which is phosphorylated by AKT. Accordingly, inhibition of AKT leads to nuclear translocation of Par-4 21 and attendant Par-4 accumulation in the nucleus (Figures 3d and e) with consequent abrogation of Fbxo45 interaction (Figure 2c) .
Overexpression of Par-4 induces apoptosis of cancer cells. 15, 16, 21 Analysis of several mutants resulting from serial deletion of the full-length Par-4 protein from both the N-and C-termini led to the identification of a unique core domain (spanning amino acids 137-195), which was previously shown to be necessary and sufficient to induce apoptosis specifically in cancer cells. 16, 19 These studies identified a unique death-inducing domain selective for apoptosis induction (SAC domain), which holds promise for exploiting key differences between cancer and normal cells that could be employed for molecular therapy of cancer. 16 A previous study demonstrated that Par-4 is cleaved by caspase-3 at D131, and the cleaved fragment of Par-4, but the not full-length Par-4, was found to accumulate in nuclear extracts after apoptosis induction. 32 Based on our data, the cleaved fragment lacks the ELNNN degron motif and thus would be protected from Fbxo45-mediated degradation. Our studies further establish that cytoplasmic Par-4 undergoes Fbxo45-mediated degradation and that Par-4 translocation into nuclear compartment protects it from Fbxo45-mediated degradation. Notably, it has been demonstrated that cells expressing wild-type Par-4 undergo apoptosis but cells expressing the C-terminal fragment of Par-4 (aa131-aa333) show up to 20% enhancement of apoptosis. 32 Our studies suggested that the C-terminal fragment may potentiate a pro-apoptotic function because the absence of VASA-like sequence protects Par-4 from Fbxo45-mediated proteasomal degradation.
Previous studies have demonstrated that Par-4 overexpression induces apoptosis and tumor regression. 17, 33 To assess the functional significance of Par-4 regulation by Figure 6 ).
In conclusion, we report that the E3 ligase Fbxo45 interacts with Par-4 through its VASA-like sequence in the cytoplasm and mediates its ubiquitylation and proteasomal degradation. Our findings uncover a hitherto unknown mechanism for the regulation of apoptosis in cancer cells via proteasomal degradation of Par-4. These results carry implication for potential exploitation of the Fbxo45-Par-4 axis in human cancer treatment.
Materials and Methods Plasmids. Fbxo45 cDNA was cloned from a K562 cell line into the pENTR/D-TOPO vector, and subcloned into a Streptavidin-Biotin-HA tandem-affinity purification (TAP)-tagged vector (kindly provided by Dr. Stephane Angers). Fulllength b-TrCP and Skp2 constructs were kindly provided by Dr. Michele Pagano and were cloned in the pIRESpuro-GLUE vector. FLAG-tagged Fbxw4, FLAGtagged Fbxw5 and FLAG-tagged Fbxw7 were kindly provided by Dr. Michele Pagano. Skp1 and Par-4 clones were purchased from Open Biosystems (Pittsburgh, PA, USA). Full-length Par-4, deletion mutants and point mutants of Par-4 were cloned in pcDNA3.1-nV5 (Invitrogen, Grand Island, NY, USA) for biochemistry experiments, and also cloned in Lenti-X Tet-On Advanced Inducible Expression System (Clontech, Mountain View, CA, USA) for biological experiments. Point mutants were generated using GeneTailor Site-Directed Mutagenesis System (Invitrogen). The deletion mutants were prepared by standard PCR procedures.
Immunoprecipitation and immunoblotting. For immunoprecipitation, cells were lysed for 20 min in IP buffer containing 50 mM HEPES pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P40, 2 mM DTT and protease inhibitor cocktail (Calbiochem, Billerica, MA, USA) on ice to get the whole-cell lysate. The cytoplasmic lysate or the nuclear lysate was extracted using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce, Rockford, IL, USA). Cell lysates were incubated with the indicated antibodies for 2 h to overnight at 4 1C and protein complexes were immunoprecipitated by Protein A/G agarose beads (Santa Cruz, Dallas, TX, USA). Immunoprecipitates were washed five times with IP buffer, eluted by heat denaturation in SDS sample buffer and analyzed by immunoblotting. After immunoblotting, blocking and antibody incubation were carried out in 5% non-fat milk in PBST, and washings in PBST. Blots were developed using ECL buffer (Thermo Scientific, Rockford, IL, USA) following the instructions of the manufacturer.
Antibody. The following antibodies were used: anti-HA (Covance, Daytona Beach, FL, USA), anti-FLAG (Sigma, St. Louis, MO, USA), anti-V5 (Invitrogen), anti-Actin (Sigma), anti-Par-4 (Abcam, Cambridge, MA, USA), anti-Skp1 (BD, San Jose, CA, USA), anti-PARP-1 B (Sigma), anti-AKT (Cell Signalling, Danvers, MA, USA), anti-P-AKT (Cell Signalling). Fbxo45 antibody was generated by Thermo Scientific Company. The peptide sequence was used to generate antisera as previously described. 10 Flow cytometry analysis. For measuring apoptosis, transfected cells were dual stained with 7-AAD (PE) and APC-Annexin V using an Alexa Fluor 488-annexin V Dead Cell apoptosis kit (Invitrogen) according to the manufacturer's protocol. Stained cells were analyzed by flow cytometry (FC 500 MPL system; Beckman Coulter, Brea, CA, USA).
In situ TUNEL assay. Apoptosis was determined by detecting DNA fragmentation using the TUNEL Assay System (Roche, Indianapolis, IN, USA) in accordance with the manufacturer's instructions. Briefly, cultured cells grown on coverslips were fixed with paraformaldehyde (4% in PBS) for 15 min and permeabilized with PBT (0.1% Triton X-100 in PBS) for 10 min. The cells were then incubated in TUNEL reaction mixture for 60 min at 37 1C. After three washes with PBS, samples were directly analyzed under the microscope.
Interactome identification using mass spectrometry. Immunoprecipitated samples (details) were resolved on SDS-PAGE, and visualized by Coomasssie stain. In-gel digestion by trypsin was carried out using procedure standardized at the Proteomics Resource Facility (University of Michigan). Tryptic peptides were resolved on a nano-capillary reverse phase column and introduced directly into a linear ion-trap mass spectrometer (LTQ XL, Thermo Fisher, Waltham, MA, USA). The mass spectrometer was set to collect one survey scan (MS1), followed by MS/MS spectra on the nine most intense ions observed in MS1 scan. Proteins were identified by searching the MS/MS spectra against human protein database using X!Tandem/TransProteomic Pipeline software suite developed by ISB (Seattle, WA, USA). All proteins identified with a probability of Z0.9 were kept for further analysis.
Cell culture and drug treatment. 293T, HeLa and PC3 cells were grown in DMEM (Invitrogen), supplemented with 10% fetal bovine serum (Invitrogen) and 0.2 mM L-glutamine (Invitrogen). Fbxo45 gene trap mES cells (SIGTR ES cell line AZ0252) were obtained from Mutant Mouse Regional Resource Center (MMRRC) program. The mES cells were grown in 1 Â GMEM medium (Sigma) supplemented with 2 mM L-glutamine (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 1 Â nonessential amino acids (Invitrogen), 10% (v/v) fetal bovine serum (Invitrogen), a 1 : 1000 dilution of b-mercaptoethanol stock solution, and 500-1000 U/ml of leukocyte inhibitory factor (Chemicon, Temecula, CA, USA). The following drugs were used: proteasome inhibitor MG132 (Sigma), CAL-101 (AKT inhibitor; Selleckchem, Houston, TX, USA), staurosporine (Sigma), doxycycline (Sigma) and cycloheximide (Sigma).
Transient transfection and lentivirus-mediated gene transfer. Cells were transfected with the use of Lipofectamine reagent (Invitrogen) or Poly jet (Signagen, Rockville, MD, USA). For lentivirus-mediated gene transfer, 293T cells were co-transfected with lentiviral vector together with packaging vectors. At 48 h after transfection, virus-containing medium was collected and supplemented with Polybrene (4 mg/ml; Sigma). Cells were then infected with the viral supernatant. The transiently transfected cells and/or the lentivirus-mediated transduced cells were selected with Puromycin (2 mg/ml) for 7-14 days to generate the stable gene-expressing cell lines.
Gene silencing by shRNA or siRNA. Lentiviral shRNA against Fbxo45 were purchased from Open Biosystems (V2LHS_182000, V2LHS_222040, V2LHS_254545).
GenomeWide siRNA of Fbxo45 was 140186437_10, Human Fbxo45 (NM_00115573.1) sequence of sense strand 5 0 -CAGAUAGGAGAAAGAAUUCGA-3 0 .
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As a control for potential off-target effects, a pool of four siCONTROL non-targeting siRNAs was used (D-001206-13). Real-time PCR. RNA was isolated from cells using RNeasy Mini kits (Qiagen, Valencia, CA, USA). cDNA was synthesized using SuperScript kit (Invitrogen). The following primer pairs were used for real-time PCR amplification: Human Fbxo45: 5 0 -AGTGCCAAGGTTATGTGGCATTGCTG-3
Quantitative real-time PCR was carried out using SYBR green (Invitrogen). Reactions were performed in triplicate according to the manufacturer's protocol. GAPDH was used as the internal control.
In vivo ubiquitylation assay. 293T cells were transfected with expression vectors encoding Skp1, HA-tagged Fbxo45, FLAG-tagged ubiquitin and V5-tagged wild-type Par-4 or mutant Par-4 (3A). At 48 h after transfection, cells were incubated with MG132 for 4 h before lysis. WCEs were subjected to immunoprecipitation with anti-V5 resin followed by blotting with the indicated antibodies.
The in vitro ubiquitylation assay. The in vitro ubiquitylation assay was performed with In vitro-translated Flag-Par-4 and its corresponding mutants as substrate. For ligase purification, TAP HA-tagged Fbxo45 E3 ligase complex was expressed and immunoprecipitated from 293T cells. Immunoprecipitates were further used for in vitro ubiquitylation assays in a volume of 100 ml, containing 2 mM ATP, 1.5 mg/ml E1, 10 mg/ml E2 (Ubch5c) and (Ube2w), 1 mM ubiquitin aldehyde, 2.5 mg/m Flag-tagged ubiquitin and protease inhibitor cocktail. The reactions were incubated at 30 1C for 45 min and analyzed by immunoblotting.
